Synergistic protection from lung damage by combining antithrombin-III and alpha 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model.
Septicemic/endotoxic-induced adult respiratory distress syndrome (ARDS) remains a major clinical problem. The present study was to determine in the E. coli endotoxemic sheep ARDS model the efficacy of combination prophylaxis with antithrombin-III (AT-III) and alpha 1-proteinase inhibitor (alpha 1-PI). We reasoned that 1) AT-III supplementation would ameliorate the endotoxin-induced coagulopathy, 2) alpha 1-PI supplementation would attenuate pulmonary damage caused by neutrophil elastase and inactivation of AT-III by neutrophil elastase, and 3) the therapeutic effects of this combination would be additive or synergistic. The typical increases in lung lymph flow microvascular permeability to protein, transvascular protein flow and transvascular protein clearance, and decrease in systemic arterial PO2 were prevented or significantly attenuated during 5 hours of endotoxemia by the AT-III/alpha 1-PI combination pretreatment. Limited efficacy was observed with AT-III pretreatment, and none was seen with alpha 1-PI alone. Results of this study demonstrate that combining AT-III and alpha 1-PI prophylaxis prevents or attenuates indices of ARDS during gram-negative endotoxemia and that this efficacy is due to a statistically significant synergism between AT-III and alpha 1-PI.
Redens
T B
TB
Department of Experimental Therapeutics, Cutter Biological, Miles Inc., Berkeley, California 94710.
Leach
W J
WJ
Bogdanoff
D A
DA
Emerson
T E
TE
D000818:Animals; D000990:Antithrombin III / Q000627:therapeutic use*; D001798:Blood Proteins / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004731:Endotoxins; D004926:Escherichia coli; D006439:Hemodynamics; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008196:Lymph / Q000502:physiology; D008297:Male; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011897:Random Allocation; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D012756:Sheep; D012772:Shock, Septic / Q000209:etiology / Q000503:physiopathology; D000515:alpha 1-Antitrypsin
D001798:Blood Proteins; D004731:Endotoxins; D011480:Protease Inhibitors; D000515:alpha 1-Antitrypsin; C044101:endotoxin, Escherichia coli; D000990:Antithrombin III